CRISPR NEWS

European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)

On April 3, 2019, the European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400) covering CRISPR-Cas9 systems, edited cells, and the use of CRISPR-Cas9 in any environment (including plant, animal and human cells). This third European patent also includes claims covering CRISPR-Cas9 compositions for use in treating human and animal diseases.

In addition to this third patent, both the first and second European patents awarded to the Doudna-Charpentier team cover the use of CRISPR-Cas9 gene editing in a broad range of cellular and noncellular settings: EP Patent No. 2 800 811 covers all uses of the single-guide format of the Cas9 system, and EP 3 241 902 coves modified Cas9 that incorporates additional DNA-modulating functions such as the regulation of gene expression.

LATEST

Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issued U.S. Patent No. 10,266,850 (‘the ‘850 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)
U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
Read moreArrow-down